

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1625JXC

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	3	OCT 19	BEILSTEIN updated with new compounds
NEWS	4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	5	NOV 19	WPIX enhanced with XML display format
NEWS	6	NOV 30	ICSD reloaded with enhancements
NEWS	7	DEC 04	LINPADOCDB now available on STN
NEWS	8	DEC 14	BEILSTEIN pricing structure to change
NEWS	9	DEC 17	USPATOLD added to additional database clusters
NEWS	10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC 17	DGENE now includes more than 10 million sequences
NEWS	12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	14	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	16	JAN 02	STN pricing information for 2008 now available
NEWS	17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	19	JAN 28	MARPAT searching enhanced
NEWS	20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	23	FEB 08	STN Express, Version 8.3, now available
NEWS	24	FEB 20	PCI now available as a replacement to DPCI
NEWS	25	FEB 25	IFIREF reloaded with enhancements
NEWS	26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	27	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:38:51 ON 27 MAR 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:39:02 ON 27 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 MAR 2008 HIGHEST RN 1010293-80-7

DICTIONARY FILE UPDATES: 26 MAR 2008 HIGHEST RN 1010293-80-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s atorvastatin?

L1 15 ATORVASTATIN?

=> s l1 and ?amorph?

LEFT TRUNCATION IGNORED FOR FILE 'REGISTRY'

420 AMORPH?

L2 0 L1 AND ?AMORPH?

Left truncation is not valid in the specified search field in the specified file. The term has been searched without left truncation. Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID' would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you used a truncation symbol after a punctuation mark, the system may interpret the truncation symbol as being at the beginning of a term. Implied proximity is used in search fields indexed as single words, for example, the Basic Index.

=> s l1 and amorphous


17 AMORPHOUS

L3 0 L1 AND AMORPHOUS

=> d 11 1-15

L1 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 915092-86-3 REGISTRY  
 ED Entered STN: 10 Dec 2006  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, phenylmethyl ester, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)  
 OTHER NAMES:  
 CN Atorvastatin benzyl ester  
 FS STEREOSEARCH  
 MF C40 H41 F N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 915092-85-2 REGISTRY  
 ED Entered STN: 10 Dec 2006  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 2-propen-1-yl ester, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 2-propenyl ester, ( $\beta$ R, $\delta$ R)- (9CI)  
 OTHER NAMES:  
 CN Atorvastatin allyl ester  
 FS STEREOSEARCH  
 MF C36 H39 F N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L1 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 874114-41-7 REGISTRY  
 ED Entered STN: 13 Feb 2006  
 CN Magnesium, bis[[( $\beta$ R, $\delta$ R)-2-(4-fluorophenyl)- $\beta$ -(hydroxy- $\omega$ O)- $\delta$ -hydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoate- $\omega$ O1]-, (T-4)- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Magnesium Atorvastatin  
 DR 928371-13-5, 956035-12-4, 947698-59-1  
 MF C66 H68 F2 Mg N4 O10  
 CI CCS  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL



13 REFERENCES IN FILE CA (1907 TO DATE)  
 13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 844874-19-7 REGISTRY  
 ED Entered STN: 10 Mar 2005  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, bismuth(3+) salt (3:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)  
 OTHER NAMES:  
 CN Tris(atorvastatin) bismuth  
 FS STEREOSEARCH  
 MF C33 H35 F N2 O5 . 1/3 Bi  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT  
 CRN (134523-00-5)

Absolute stereochemistry.




● 1/3 Bi(III)

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 501121-34-2 REGISTRY  
 ED Entered STN: 01 Apr 2003  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ S, $\delta$ S)- (CA INDEX NAME)  
 OTHER NAMES:  
 CN 3S,5S-Atorvastatin  
 FS STEREOSEARCH  
 MF C33 H35 F N2 O5  
 SR CA  
 LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 344423-98-9 REGISTRY  
 ED Entered STN: 03 Jul 2001  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt, hydrate (2:1:3), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), trihydrate, ( $\beta$ R, $\delta$ R)- (9CI)  
 OTHER NAMES:  
 CN Atorvastatin hemicalcium sesquihydrate  
 CN Atorvastatin hemicalcium trihydrate  
 FS STEREOSEARCH  
 MF C33 H35 F N2 O5 . 1/2 Ca . 3/2 H2 O  
 CI COM  
 SR CA  
 LC STN Files: CA, CAPLUS, MRCK\*, PATDPASPC, TOXCENTER, USPAT2, USPATFULL (\*File contains numerically searchable property data)  
 CRN (134523-00-5)

Absolute stereochemistry.




● 1/2 Ca

● 3/2 H<sub>2</sub>O

13 REFERENCES IN FILE CA (1907 TO DATE)  
 13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 340266-37-7 REGISTRY  
 ED Entered STN: 11 Jun 2001  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, monoammonium salt, ( $\beta$ R, $\delta$ R)- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Atorvastatin ammonium salt  
 FS STEREOSEARCH  
 MF C33 H35 F N2 O5 . H3 N  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 CRN (134523-00-5)

Absolute stereochemistry.




● NH<sub>3</sub>

6 REFERENCES IN FILE CA (1907 TO DATE)  
 6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 214217-88-6 REGISTRY  
 ED Entered STN: 12 Nov 1998  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-4-[[[(4-hydroxyphenyl)amino]carbonyl]-5-(1-methylethyl)-3-phenyl-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)  
 OTHER NAMES:  
 CN BMS 241423-01  
 CN p-Hydroxyatorvastatin  
 CN PD 142542  
 FS STEREOSEARCH  
 MF C33 H35 F N2 O6  
 CI COM  
 SR CA  
 LC STN Files: ANABSTR, CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

23 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 23 REFERENCES IN FILE CAPLUS (1907 TO DATE)



L1 ANSWER 13 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 134523-00-5 REGISTRY  
 ED Entered STN: 28 Jun 1991  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, [R-(R\*,R\*)]-  
 OTHER NAMES:  
 CN ( $\beta$ R, $\delta$ R)-2-(p-Fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid  
 CN (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid  
 CN Atorvastatin  
 CN Atorvastatin acid  
 CN Cardyl  
 FS STEREOSEARCH  
 MF C33 H35 F N2 O5  
 CI CCM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, HSDB\*, IMSCSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH, SYNTLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3252 REFERENCES IN FILE CA (1907 TO DATE)  
 76 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 3288 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 15 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 125995-03-1 REGISTRY  
 ED Entered STN: 23 Mar 1990  
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-, (2R-trans)-  
 OTHER NAMES:  
 CN 5-(4-Fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-oxotetrahydropyran-2-yl]ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide  
 CN Atorvastatin  $\delta$ -lactone  
 CN Atorvastatin lactone  
 FS STEREOSEARCH  
 DR 142062-65-5  
 MF C33 H33 F N2 O4  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, MRCK\*, PS, TOXCENTER, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

77 REFERENCES IN FILE CA (1907 TO DATE)  
 77 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 134395-00-9 REGISTRY  
 ED Entered STN: 21 Jun 1991  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 1,1-dimethylethyl ester, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 1,1-dimethylethyl ester, [R-(R\*,R\*)]-  
 OTHER NAMES:  
 CN (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid tert-butyl ester  
 CN Atorvastatin tert-butyl ester  
 FS STEREOSEARCH  
 MF C37 H43 F N2 O5  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, PS, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

26 REFERENCES IN FILE CA (1907 TO DATE)  
 26 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	46.83	47.04

FILE 'CAPLUS' ENTERED AT 12:40:34 ON 27 MAR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Mar 2008 VOL 148 ISS 13  
FILE LAST UPDATED: 26 Mar 2008 (20080326/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>



L6 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:492770 CAPLUS  
DOCUMENT NUMBER: 147:413032  
TITLE: Process for manufacturing amorphous atorvastatin calcium  
INVENTOR(S): Vakil, Manish H.; Purohit, Parva Y.; Kumar, Sharma Rajiv; Kumar, Agarwal Virendra  
PATENT ASSIGNEE(S): Cadila Healthcare Limited, India  
SOURCE: Indian Pat. Appl., 22pp.  
CODEN: INXXBQ  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2004MU00758	A	20070427	IN 2004-MU758	20040716

PRIORITY APPLN. INFO.: IN 2004-MU758 20040716

AB The present invention relates to convenient preparation of amorphous atorvastatin calcium by spray drying the solution of atorvastatin calcium in comprising hydroxylic solvent system or the other solvent system that has got higher evaporation rate.

IT 134523-03-8P, Atorvastatin calcium  
RL: PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (process for manufacturing amorphous atorvastatin calcium)  
RN 134523-03-8 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2006:1176938 CAPLUS  
DOCUMENT NUMBER: 145:505324  
TITLE: A process for the production of amorphous atorvastatin calcium  
INVENTOR(S): Reddy, Manne Satyanarayana; Nagaraju, Chakilam; Srinivasulu, Gudipati; Srinivas, Katakam  
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Limited, India  
SOURCE: Indian, 16pp.  
CODEN: INXXAP  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 193427	A1	20040717	IN 2001-MA949	20011122


PRIORITY APPLN. INFO.: IN 2001-MA949 20011122

OTHER SOURCE(S): CASREACT 145:505324  
AB A process for the production of amorphous atorvastatin calcium comprises: (A) heating a mixture of [R-(R\*,R\*)]-2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-[(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid alkyl ester (e.g., tert-Bu ester), allyl ester, or benzyl ester with a nitrile (e.g., acetonitrile) and an alkali (e.g., sodium hydroxide) to about 25-60°; (B) maintaining the reaction mixture of step (A) at 25-60° for about 3-9 h; (C) adding to the step (B) reaction mixture an aqueous solution of a calcium salt (e.g., calcium acetate hemihydrate); (D) further stirring the reaction mixture at 30-50° for about 30 min to 2 h; (E) filtering the reaction solution obtained in step (D); (F) distilling the solvent from the reaction solution of step (E) to yield a residue; (G) dissolving the residue of step (F) in non-hydroxylic polar solvent (e.g., MIBK); (H) distilling the solvent of step (G) and subsequently adding a non-polar hydrocarbon solvent (e.g., cyclohexane); and (I) isolating the obtained amorphous Atorvastatin calcium by filtration or other known methods.

IT 134395-00-9, Atorvastatin tert-butyl ester 915092-85-2, Atorvastatin allyl ester 915092-86-3, Atorvastatin benzyl ester  
RL: RCT (Reactant); RACT (Reactant or reagent) (in a process for the production of amorphous atorvastatin calcium)  
RN 134395-00-9 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 1,1-dimethylethyl ester, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 915092-85-2 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, 2-propen-1-yl ester, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 915092-86-3 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, phenylmethyl ester, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



IT 134523-03-8P, Atorvastatin calcium  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (process for the production of amorphous atorvastatin calcium)  
RN 134523-03-8 CAPLUS

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



●1/2 Ca

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN  
ACCESSION NUMBER: 2006:411701 CAPLUS  
DOCUMENT NUMBER: 144:419647  
TITLE: Process for forming amorphous atorvastatin  
INVENTOR(S): Debettencourt, Antone John, III; Rose, Peter Robert;  
Shalae, Evgeniy Yur'evich; Quallich, George Joseph;  
Ziegler, Carl Bernard  
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA  
SOURCE: PCT Int. Appl., 22 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006046109	A1	20060504	WO 2005-IB3173	20051012
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005298383	A1	20060504	AU 2005-298383	20051012
CA 2585836	A1	20060504	CA 2005-2585836	20051012
EP 1807055	A1	20070718	EP 2005-796593	20051012
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 101048141	A	20071003	CN 2005-80037285	20051012
IN 2007DN02889	A	20070817	IN 2007-DN2889	20070418
MX 200704722	A	20070615	MX 2007-4722	20070419
KR 2007067175	A	20070627	KR 2007-709632	20070427
PRIORITY APPLN. INFO.:			US 2004-623086P	P 20041028
			WO 2005-IB3173	W 20051012

AB A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin. Amorphous atorvastatin calcium was obtained by freeze-drying from a solution of DMSO.  
IT 134523-00-5P, Atorvastatin 134523-03-8P, Atorvastatin calcium  
RL: PNU (Preparation, unclassified); PRP (Properties); PREP (Preparation) (process for forming amorphous atorvastatin)  
RN 134523-00-5 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)-


L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN  
ACCESSION NUMBER: 2005:115424 CAPLUS  
DOCUMENT NUMBER: 143:410962  
TITLE: Process for forming amorphous atorvastatin calcium  
INVENTOR(S): Rose, Peter Robert; Leonard, Jason Albert  
PATENT ASSIGNEE(S): Pfizer Products Inc., USA  
SOURCE: PCT Int. Appl., 18 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100313	A1	20051027	WO 2005-IB884	20050404
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005232959	A1	20051027	AU 2005-232959	20050404
CA 2562844	A1	20051027	CA 2005-2562844	20050404
EP 1742910	A1	20070117	EP 2005-718356	20050404
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1960972	A	20070509	CN 2005-80017687	20050404
BR 2005009923	A	20070918	BR 2005-9923	20050404
JP 2007532622	T	20071115	JP 2007-507860	20050404
US 2007225353	A1	20070927	US 2006-578084	20061012
MX 2006Pall1987	A	20070116	MX 2006-Pall1987	20061016
IN 2006DN06030	A	20070427	IN 2006-DN6030	20061016
WO 2006005229	A	20061114	WO 2006-5229	20061114
PRIORITY APPLN. INFO.:			US 2004-562948P	P 20040416
			WO 2005-IB884	W 20050404

AB Forming amorphous atorvastatin calcium comprises the steps of dissolving atorvastatin calcium in a solvent to form a solution, followed by adding the solution to a mixture comprising a non-solvent and a hydroxylic solvent to afford amorphous atorvastatin.  
IT 134523-00-5, Atorvastatin 134523-03-8, Atorvastatin calcium  
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (process for forming amorphous atorvastatin calcium)  
RN 134523-00-5 CAPLUS


L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 134523-03-8 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 134523-03-8 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN  
ACCESSION NUMBER: 2004:1036720 CAPLUS  
DOCUMENT NUMBER: 142:28246  
TITLE: Process for preparation of amorphous atorvastatin calcium  
INVENTOR(S): Sebastian, Sonny; Devarasetty, Sitaramaiah; Dandala, Ramesh; Sivakumaran, Meenakshisunderam  
PATENT ASSIGNEE(S): India  
SOURCE: U.S. Pat. Appl. Publ., 13 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242670	A1	20041202	US 2004-858261	20040601
PRIORITY APPLN. INFO.:			IN 2003-MA438	A 20030602
			IN 2003-MA439	A 20030602

AB Process for the preparation of amorphous form of atorvastatin calcium from crystalline atorvastatin calcium or from a mixture of crystalline and amorphous atorvastatin calcium by spray drying or by pulverization method is described. For example, 15 g of crystalline atorvastatin calcium dissolved in 100 mL of methanol were spray dried at a temperature of 58° to 62° using nitrogen as drying gas until a white amorphous powder of atorvastatin calcium was obtained. The amorphous material thus obtained was dried under reduced pressure till LOD 0.5%, having residual solvent level of 0.015% for methanol. Purity of amorphous atorvastatin calcium obtained was 98.7%.

IT 134523-03-8, Atorvastatin calcium  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(preparation of amorphous atorvastatin calcium by spray drying or pulverization method)

RN 134523-03-8 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN  
ACCESSION NUMBER: 2004:878372 CAPLUS  
DOCUMENT NUMBER: 141:337649  
TITLE: Process for the preparation of amorphous calcium salt of atorvastatin  
INVENTOR(S): Antoncic, Ljubomir; Sorsak, Gorazd; Copar, Anton  
PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia  
SOURCE: PCT Int. Appl., 30 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089895	A1	20041021	WO 2004-SI19	20040409
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GE, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
SI 21461	A	20041031	SI 2003-100	20030411
SI 21505	A	20041231	SI 2003-138	20030606
AU 2004228607	A1	20041021	AU 2004-228607	20040409
CA 2520740	A1	20041021	CA 2004-2520740	20040409
EP 1615884	A1	20060118	EP 2004-726842	20040409
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
HR				
BR 2004009292	A	20060411	BR 2004-9292	20040409
US 2006287538	A1	20061221	US 2005-552562	20051011
PRIORITY APPLN. INFO.:			SI 2003-100	A 20030411
			SI 2003-138	A 20030606
			WO 2004-SI19	A 20040409

OTHER SOURCE(S): MARPAT 141:337649  
AB Present invention refers to the process of preparing amorphous atorvastatin calcium without intermediate isolation of crystal or undefined mixture of crystal and amorphous atorvastatin calcium, resp. Forming of calcium atorvastatin salt is carried out in a mixture of chlorinated organic solvent or cyclic hydrocarbon solvent, resp., the non-hydroxylic organic solvent, and water, the source of calcium ions is calcium acetate or calcium chloride, resp. Atorvastatin calcium was prepared by the reaction of atorvastatin in THF with aqueous solution of calcium acetate monohydrate which was then separated and dried.

IT 134523-00-5, Atorvastatin  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(process for preparation of amorphous calcium salt of atorvastatin)

RN 134523-00-5 CAPLUS


L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)



● 1/2 Ca

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



IT 134523-03-8, Atorvastatin calcium  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(process for preparation of amorphous calcium salt of atorvastatin)

RN 134523-03-8 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



● 1/2 Ca

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:55459 CAPLUS  
DOCUMENT NUMBER: 137:114534  
TITLE: Atorvastatin calcium crystal forms  
INVENTOR(S): Joy, Mathew; Ganesh, Sambasivam  
PATENT ASSIGNEE(S): Biocon India Limited, India  
SOURCE: PCT Int. Appl., 14 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002057228	A1	20020725	WO 2001-IN4	20010117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
AU 2001234057	A1	20020730	AU 2001-234057	20010117
PRIORITY APPLN. INFO.:			WO 2001-IN4	W 20010117


AB A process for the preparation of amorphous atorvastatin calcium and its hydrates thereof comprise: (a) dissolving heterogeneous mixture of atorvastatin calcium in a non-hydroxylic solvent; (b) adding a non-hydroxylic solvent or adding the dissolved atorvastatin to the non-hydroxylic solvent to precipitate out atorvastatin calcium; and (c) removing the solvent by filtration to afford amorphous atorvastatin calcium.

IT 134523-03-8, Atorvastatin hemicalcium salt  
RL: FMU (Formation, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use);  
BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process);  
USES (Uses)  
(atorvastatin calcium crystal forms)

RN 134523-03-8 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2000:841975 CAPLUS  
DOCUMENT NUMBER: 134:21435  
TITLE: Process for the production of amorphous atorvastatin calcium  
INVENTOR(S): Kumar, Yatendra; Thaper, Rajesh Kumar; Kumar, S. M. Dileep  
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India  
SOURCE: PCT Int. Appl., 16 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071116	A1	20001130	WO 2000-IB14	20000106
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IN 191236	A1	20031011	IN 1999-DE775	19990525
EP 1185264	A1	20020313	EP 2000-900300	20000106
EP 1185264	B1	20070523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK				
BR 2000010923	A	20020716	BR 2000-10923	20000106
AU 778962	B2	20041223	AU 2000-19967	20000106
CN 1680315	A	20051012	CN 2005-10052583	20000106
AT 362759	T	20070615	AT 2000-900300	20000106
ES 2284472	T3	20071116	ES 2000-900300	20000106
ZA 2001009656	A	20020627	ZA 2001-9656	20011123
US 6528660	B1	20030304	US 2002-979475	20020212
US 2003149279	A1	20030807	US 2003-378574	20030303
PRIORITY APPLN. INFO.:			IN 1999-DE775	A 19990525

CN 2000-808027 A3 20000106  
WO 2000-IB14 W 20000106  
US 2002-979475 A1 20020212


AB A process for the preparation of amorphous atorvastatin calcium and hydrates comprises: (a) dissolving crystalline atorvastatin calcium in a non-hydroxylic solvent; (b) adding a non-polar hydrocarbon anti-solvent or adding the dissolved atorvastatin to the non-polar anti-solvent to precipitate out atorvastatin calcium; and (c) removing the solvent by filtration to afford amorphous atorvastatin calcium.

IT 134523-03-8, Atorvastatin calcium  
RL: PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

(process for the prodn. of amorphous atorvastatin calcium)  
RN 134523-03-8 CAPLUS  
CN 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

ACCESSION NUMBER: 1997:204226 CAPLUS  
DOCUMENT NUMBER: 126:199450  
TITLE: Preparation of atorvastatin in an amorphous form  
INVENTOR(S): Lin, Min; Schweiss, Dieter  
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Lin, Min; Schweiss, Dieter  
SOURCE: PCT Int. Appl., 22 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9703960	A1	19970206	WO 1996-US11807	19960716
W: AU, BG, BR, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
HR 960312	B1	20011031	HR 1996-312	19960703
CA 2220455	A1	19970206	CA 1996-2220455	19960716
CA 2220455	C	20020924		
AU 9664978	A	19970218	AU 1996-64978	19960716
AU 700794	B2	19990114		
EP 839132	A1	19980506	EP 1996-924553	19960716
EP 839132	B1	20010307		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1190956	A	19980819	CN 1996-195631	19960716
CN 1087289	B	20020710		
BR 9609714	A	19990223	BR 1996-9714	19960716
IL 122161	A	19990714	IL 1996-122161	19960716
JP 11510486	T	19990914	JP 1997-506814	19960716
JP 4064459	B2	20080319		
NZ 313008	A	20000128	NZ 1996-313008	19960716
IN 185276	A1	20001216	IN 1996-DE1579	19960716
HU 9903017	A3	20010129	HU 1999-3017	19960716
HU 220343	B	20011228		
AT 199542	T	20010315	AT 1996-924553	19960716
ES 2156997	T3	20010801	ES 1996-924553	19960716
CZ 289421	B6	20020116	CZ 1998-122	19960716
EE 3605	B1	20020215	EE 1997-369	19960716
SK 283204	B6	20030304	SK 1998-58	19960716
RO 120069	B1	20050830	RO 1998-60	19960716
PL 191017	B1	20060331	PL 1996-324463	19960716
ZA 9606043	A	19970203	ZA 1996-6043	19960717
BG 63631	B1	20020731	BG 1998-102188	19980114
US 6087511	A	20000711	US 1998-983369	19980115
NO 9800209	A	19980116	NO 1998-209	19980116
NO 309322	B1	20010115		
HK 1018054	A1	20021101	HK 1998-113382	19981215
US 6274740	B1	20010814	US 2000-657469	20000907
GR 3035859	T3	20010831	GR 2001-400710	20010515
PRIORITY APPLN. INFO.:			US 1995-1453P	P 19950717
			WO 1996-US11807	W 19960716

AB The title process comprises dissolving crystalline Form I atorvastatin in a non-hydroxylic solvent and removal of the solvent to give amorphous atorvastatin.  
IT 134523-03-8P  
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
RN (preparation of atorvastatin in an amorphous form)  
CN 134523-03-8 CAPLUS  
1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)- $\beta$ , $\delta$ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), ( $\beta$ R, $\delta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



● 1/2 Ca

IT 125995-03-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
RN (preparation of atorvastatin in an amorphous form)  
CN 125995-03-1 CAPLUS  
1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	57.81	104.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

STN INTERNATIONAL LOGOFF AT 12:43:39 ON 27 MAR 2008